Business Wire

AMNIMO

23.3.2020 07:02:05 CET | Business Wire | Press release

Share
amnimo Inc. Starts Development of High-performance, Robust LTE Gateway (Edge Gateway) for Industrial Use

amnimo Inc. (Headquarters: Musashino City, Tokyo; President & CEO: Koichi [Casey] Taniguchi; hereafter, “amnimo”) starts developing an industrial-use LTE gateway, “Edge Gateway,” which is equipped with rich computing resources and a high level of robustness.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200322005056/en/

IoT is a mechanism by which a variety of devices are connected to each other via the network or the cloud service; these devices exchange information with each other. Recently, numerous approaches to the use of industrial-use IoT (IIoT) have been evolving in all types of industries. As IIoT continues to proliferate, examples of user work process improvements are increasing, but at the same time, we are witnessing operational issues such as suppressing failures in harsh external environments and being able to remotely deal with failures without going to the site. There have also been requests to process large volumes of data, such as video, using Edge in an advanced manner.

To resolve such issues, amnimo is developing the “Edge Gateway,” which is optimized for IIoT. The objective is to equip the Edge Gateway with LTE communication features that can be used in a wide variety of industries; in particular, to develop an optimal design for use in surveillance-camera systems.

[Characteristics of the Edge Gateway]

  1. Wide operating temperature range and power voltage range. Equipped with power circuits that are robust against noise and sudden outages, it has features for automatic recovery in case of a failure. This helps achieve stable operation even in harsh outdoor environments.
  2. Equipped with 2 GB of RAM and 32 GB eMMC for program storage space as the standard configuration, it can also be operated using a 2-TB SSD (Solid State Drive), enabling large-volume video data to be stored within the Edge Gateway.
  3. Equipped with a power-supply function for PoE(*1) compatible devices, it can be directly connected to a maximum of four IP cameras without using a PoE hub.
  4. The communication modules can accommodate two types of plastic SIM cards and eSIMs for a maximum of four different carrier SIMs, enabling the user to bypass communication failures by switching SIMs at high speeds in cases of emergency.
  5. Customer app development is possible on the Ubuntu OS; in addition, software development kits are provided for partners.
  6. Equipped with a VMS (Video Management System (*2)) as standard, simplifying the process of constructing small-, medium-, and large-scale surveillance systems.
  7. An extension port slot is internally provided in the Edge Gateway, enabling smooth addition of future functional extensions.

*1 Power over Ethernet: Specification wherein power is provided to the connected device(s) using Ethernet communication cables.
*2 System for saving and managing video captured using a surveillance camera.

In addition, we are developing a “device management system” to resolve issues related to operation on IIoT devices, such as the Edge Gateway. This device management system is a cloud service that enables initial configuration of IIoT devices, remote configuration and firmware updates, management of installation location, equipment life monitoring, log collection during operation, problem analysis and replacement, and transfer of configuration data for troubleshooting, thereby reducing the burden on the operator.

amnimo provides customer support for IIoT service and surveillance-camera systems, with the following objectives: “fast response and resolution for customer issues,” “value creation and innovation,” and “aim to grow with partners.”

About amnimo

amnimo was formed as a solely owned subsidiary of Yokogawa Electric Corporation as a new business to provide Industrial Internet of Things (IIoT) services in May 2018. With an excellent mobility, amnimo makes a swift decision and develops its business in a rapidly changing market. amnimo strengthens collaboration with customers and partner companies in various fields and countries to create new shared values by leveraging IIoT technologies.

To learn more, please visit https://amnimo.com/en/

The company names, organization names, and product names used in the document are registered trademarks or trademarks of the relevant organizations.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye